1390643-75-0

Upstream product

• 4049-39-2 4-benzyloxy-3-hydroxy-benzaldehyde 
• 100-39-0 benzyl bromide 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 172919-15-2 ethyl 3-(3'-hydroxy-4'-benzyloxyphenyl)-2E-propenoate 
• 1390644-08-2 (1S,2S)-1-(4-(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)phenyl)-3-(2,4-bis(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)phenyl)propane-1,2-diol 
• 1390644-05-9 (E)-(2-(benzyloxy)-5-(3-(2,4-bis(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)phenyl)prop-1-en-1-yl)phenoxy)(tert-butyl)dimethylsilane 
• 1390644-02-6 (E)-3,5-bis(benzyloxy)-2-(3-(4-(benzyloxy)-3-hydroxyphenyl)allyl)phenol 
• 1390644-01-5 (E)-2-(benzyloxy)-5-(3-hydroxyprop-1-en-1-yl)phenol 
• 1390643-72-7 (2R,3S)-5,7,4'-tri-O-benzyl-3-O-acetylcatechin 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1390643-69-2 C₃₆H₃₄O₇ 

Downstream Products

• 1390643-78-3 (2R,3S)-3'-O-(tert-butyldimethylsilyl)-5,7,4'-tri-O-benzylcatechin 
• 1390643-81-8 (2R)-3'-(tert-butyldimethylsilyloxy)-5,7,4'-tribenzyloxyflavan-3-one 
• 1390643-84-1 (2R,3R)-3'-O-(tert-butyldimethylsilyl)-5,7,4'-tri-O-benzyl-epi-catechin 
• 1390643-87-4 (2R,3R)-3'-(tert-butyldimethylsilyl)-5,7,4'-tri-O-benzyl-3-acetylepicatechin 
• 1390643-89-6 (2R,3R)-5,7,4'-tri-O-benzyl-3-acetylepicatechin 
• 1390643-91-0 C₅₁H₅₀O₁₆ 
• 1390644-13-9 C₅₁H₅₀O₁₆ 
• 1390643-95-4 (2R,3R)-5,7,4'-tri-O-benzylepicatechin 
• 1390643-97-6 (2R,3R)-5,7,4'-tri-O-benzylepicatechin-3'-O-neopentylsulfonate 
• 1390643-99-8 sodium (2R,3R)-5,7,4'-tri-O-benzylepicatechin-3'-O-sulfonate 
• 1422182-77-1 sodium (2R,3R)-epicatechin-3'-O-sulfonate 

Relevant academic research and scientific papers

Epicatechin B-ring conjugates: First enantioselective synthesis and evidence for their occurrence in human biological fluids

Herein, the first enantioselective total synthesis of a number of biologically relevant (-)-epicatechin conjugates is described. The success of this synthesis relied on (i) optimized conditions for the stereospecific cyclization step leading to the catechin C ring; on (ii) efficient conjugation reactions; and on (iii) optimized deprotection sequences. These standard compounds have been subsequently used to elucidate for the first time the pattern of (-)-epicatechin conjugates present in four different human biological fluids following (-)-epicatechin absorption.